Results 111 to 120 of about 16,077 (204)

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

open access: yesAustralasian Journal of Dermatology, Volume 67, Issue 5, Page 301-308, August 2026.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim   +7 more
wiley   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, Volume 81, Issue 8, Page 2815-2832, August 2026.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

Changes in choroidal and retinal thickness 6 months before and during 18 months of orthokeratology lens treatment in myopic children

open access: yesActa Ophthalmologica, Volume 104, Issue 5, Page e578-e589, August 2026.
Abstract Purpose To investigate changes in choroidal and retinal thickness before and during myopia control treatment with orthokeratology lenses (OKL) in myopic children. Methods This was a sub‐study of CONTROL and CONTROL2 studies. The present study was a 2‐year, prospective, single‐group interventional study consisting of a 6‐month pre‐treatment ...
P. O. Hansen, F. Møller, T. M. Jakobsen
wiley   +1 more source

Patient‐Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next‐Generation Allergen Immunotherapy

open access: yesClinical &Experimental Allergy, Volume 56, Issue 8, Page 881-892, August 2026.
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić   +10 more
wiley   +1 more source

The Prevalence of Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis and Asthma among Adults of Tehran

open access: yesIranian Journal of Public Health, 2018
Background: Alteration of environmental factors and air pollution affects the trend of allergic diseases especially in cities such as Tehran. This study aimed to determine the prevalence of allergic rhinitis, conjunctivitis, atopic dermatitis and asthma ...
Raheleh SHOKOUHI SHOORMASTI   +12 more
doaj  

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1359-1371, August 2026.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang   +18 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

[Allergic conjunctivitis].

open access: yesBoletin medico del Hospital Infantil de Mexico, 1993
The eye reacts to foreign substances through a variety of specific and non-specific defense mechanisms. Constantly exposed to a great variety of microorganisms, the eye is capable of protecting itself without altering its own structure and function. Its resistance relies upon anatomic and physiological properties of its external components (eyelids ...
B E, Del Río-Navarro   +3 more
openaire   +1 more source

Corneal tomographic and densitometric characteristics in children with allergic conjunctivitis: a comparative pentacam AXL study. [PDF]

open access: yesBMC Ophthalmol
Karakiraz A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy